We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioTelemetry (BEAT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.
BioTelemetry is a member of our Medical group, which includes 757 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 13.06% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that BEAT has returned about 99.16% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 6.75% on a year-to-date basis. As we can see, BioTelemetry is performing better than its sector in the calendar year.
To break things down more, BEAT belongs to the Medical Services industry, a group that includes 31 individual companies and currently sits at #99 in the Zacks Industry Rank. On average, stocks in this group have gained 28.69% this year, meaning that BEAT is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioTelemetry (BEAT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.
BioTelemetry is a member of our Medical group, which includes 757 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 13.06% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that BEAT has returned about 99.16% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 6.75% on a year-to-date basis. As we can see, BioTelemetry is performing better than its sector in the calendar year.
To break things down more, BEAT belongs to the Medical Services industry, a group that includes 31 individual companies and currently sits at #99 in the Zacks Industry Rank. On average, stocks in this group have gained 28.69% this year, meaning that BEAT is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.